BlackRock
BBIO icon

BlackRock’s BridgeBio Pharma BBIO Stock Holding History

BlackRock’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$766M Sell
10,287,156
-3,920,601
-28% -$275M 0.01% 915
2026
Q1 		$1.06B Sell
14,207,757
-341,772
-2% -$24.8M 0.02% 667
2025
Q4 		$1.11B Buy
14,549,529
+138,326
+1% +$9.08M 0.02% 639
2025
Q3 		$749M Buy
14,411,203
+151,724
+1% +$7.4M 0.01% 820
2025
Q2 		$616M Buy
14,259,479
+901,983
+7% +$32.8M 0.01% 918
2025
Q1 		$462M Sell
13,357,496
-352,150
-3% -$11.9M 0.01% 1096
2024
Q4 		$376M Buy
13,709,646
+830,136
+6% +$21.5M 0.01% 1268
2024
Q3 		$328M Buy
12,879,510
+431,238
+3% +$11.3M 0.01% 1367
2024
Q2 		$315M Buy
12,448,272
+1,981,337
+19% +$54.2M 0.01% 1314
2024
Q1 		$324M Buy
10,466,935
+310,162
+3% +$10.5M 0.01% 1313
2023
Q4 		$410M Buy
10,156,773
+906,830
+10% +$27.2M 0.01% 1153
2023
Q3 		$244M Sell
9,249,943
-331,786
-3% -$9.42M 0.01% 1410
2023
Q2 		$165M Buy
9,581,729
+463,948
+5% +$6.98M ﹤0.01% 1716
2023
Q1 		$151M Sell
9,117,781
-650,410
-7% -$7.58M ﹤0.01% 1753
2022
Q4 		$74.4M Buy
9,768,191
+502,323
+5% +$4.81M ﹤0.01% 2211
2022
Q3 		$92.1M Sell
9,265,868
-92,713
-1% -$963K ﹤0.01% 2018
2022
Q2 		$85M Buy
9,358,581
+214,374
+2% +$1.79M ﹤0.01% 2127
2022
Q1 		$92.8M Sell
9,144,207
-131,383
-1% -$1.35M ﹤0.01% 2186
2021
Q4 		$155M Sell
9,275,590
-865,721
-9% -$36.6M ﹤0.01% 1919
2021
Q3 		$475M Buy
10,141,311
+640,990
+7% +$34.4M 0.01% 1017
2021
Q2 		$579M Buy
9,500,321
+427,684
+5% +$24.4M 0.02% 900
2021
Q1 		$559M Buy
9,072,637
+2,555,093
+39% +$167M 0.02% 911
2020
Q4 		$463M Buy
6,517,544
+397,407
+6% +$19.2M 0.01% 952
2020
Q3 		$230M Buy
6,120,137
+561,651
+10% +$17.7M 0.01% 1281
2020
Q2 		$181M Buy
5,558,486
+335,888
+6% +$10.2M 0.01% 1437
2020
Q1 		$151M Buy
5,222,598
+2,562,875
+96% +$79.5M 0.01% 1364
2019
Q4 		$93.2M Buy
2,659,723
+1,184,951
+80% +$32.8M ﹤0.01% 2007
2019
Q3 		$31.7M Buy
1,474,772
+1,421,272
+2,657% +$39.3M ﹤0.01% 2551
2019
Q2 		$1.44M Buy
+53,500
New +$1.46M ﹤0.01% 3890

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock's BBIO Position: Q2 2026 in Review

BlackRock reduced its BridgeBio Pharma (BBIO) stake by 28% in Q2 2026, selling an estimated $275M and leaving 10,287,156 shares worth $766M. The position accounts for 0.01% of the portfolio, ranked #915.

BlackRock first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.11B in Q4 2025. 473 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • BlackRock held 10,287,156 shares of BridgeBio Pharma worth $766M as of Q2 2026.
  • BlackRock sold 3,920,601 BridgeBio Pharma shares in Q2 2026, an estimated $275M.
  • BridgeBio Pharma made up 0.01% of BlackRock's portfolio in Q2 2026, its #915 holding.
  • BlackRock first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • BlackRock's BridgeBio Pharma position peaked at $1.11B in Q4 2025.
  • 473 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.